XXII Reddit Mentions | ChartExchange

With the current **Aditxt (NASDAQ: ADTX)** share price sitting at a deeply depressed **$0.0109**, the company can no longer rely on quick-fix financial engineering like reverse splits. This limitation stems from recent SEC/Nasdaq rule tightening, which severely restricts consecutive splits for chronically non-compliant penny stocks. \[[1](https://www.publiccompanyadvisoryblog.com/2025/02/20/new-nasdaq-and-nyse-delisting-rules-restrict-use-of-reverse-stock-splits/), [2](https://www.google.com/finance/quote/ADTX:NASDAQ), [3](https://finance.yahoo.com/news/aditxt-inc-nasdaq-adtx-announces-133000476.html), [4](https://stocktwits.com/news-articles/markets/equity/adtx-stock-crashes-third-reverse-split-announcement/cZX1Uv9ReSO)\]
Because of this, newly appointed Interim CEO Jeffrey M. Busch is pivoting the corporate strategy away from portfolio acquisition and toward intense operational and commercial execution to organically drive the stock price. \[[1](https://public.com/stocks/adtx), [2](https://www.theglobeandmail.com/investing/markets/stocks/ADTX/pressreleases/2259544/aditxt-appoints-interim-ceo-amid-broad-leadership-transition/), [3](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]
**The New CEO’s Strategy to Lift the Stock Price**
Instead of relying on accounting tricks, Jeffrey Busch—who brings significant credibility from building a **$1 billion NYSE-listed healthcare enterprise**—is focusing on fundamental business benchmarks to rescue the company's valuation: \[[1](https://public.com/stocks/adtx), [2](https://www.theglobeandmail.com/investing/markets/stocks/ADTX/pressreleases/2259544/aditxt-appoints-interim-ceo-amid-broad-leadership-transition/), [3](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]
**Commercializing Ignite Proteomics:** The plan aggressively centers on Aditxt's subsidiary, [Ignite Proteomics](https://finance.yahoo.com/sectors/healthcare/articles/aditxt-inc-appoints-jeffrey-m-121500584.html). Rather than broadly chasing new startups, the company is funneling resources into commercializing Ignite’s precision oncology diagnostic platform. \[[1](https://finance.yahoo.com/sectors/healthcare/articles/aditxt-inc-appoints-jeffrey-m-121500584.html), [2](https://seekingalpha.com/news/4598884-aditxt-appoints-jeffrey-m-busch-as-interim-ceo), [3](https://www.theglobeandmail.com/investing/markets/stocks/ADTX/pressreleases/2259544/aditxt-appoints-interim-ceo-amid-broad-leadership-transition/), [4](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]
**Generating Immediate Revenue:** Ignite already has an established **Medicare reimbursement pathway** (a dedicated PLA code) and clinical collaborations with high-profile organizations like the Dana-Farber Cancer Institute. The strategy is to turn these into rapid, recurring revenue scales to legally prove financial viability to Nasdaq. \[[1](https://finance.yahoo.com/sectors/healthcare/articles/aditxt-inc-appoints-jeffrey-m-121500584.html), [2](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]
**Validating Large-Scale Data:** In early June, Aditxt signed a definitive agreement valuing Ignite at **$150 million** and announced a prospective 10,000-patient oncology registry. Busch plans to leverage this clinical validation to attract institutional investors. \[[1](https://public.com/stocks/adtx), [2](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]
**Instilling Restructured Capital Discipline:** Busch's mandate includes halting erratic capital market plays and introducing transparency. By cleaning up the balance sheet through measured private placements ($1.25 million in unsecured notes), the goal is to organically restore the equity requirements needed for compliance. \[[1](https://www.theglobeandmail.com/investing/markets/stocks/ADTX/pressreleases/2259544/aditxt-appoints-interim-ceo-amid-broad-leadership-transition/), [2](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/), [3](https://www.investing.com/news/company-news/aditxt-names-jeffrey-busch-as-interim-ceo-93CH-4719172), [4](https://www.stocktitan.net/sec-filings/XXII/8-k-22nd-century-group-inc-reports-material-event-1f50733d447f.html)\]
**The Ultimate Goal: Organic Recovery or OTC Pivot**
The immediate operational focus is designed to build a fundamental base strong enough to pump the micro-cap stock back toward compliance organically. However, if the business execution cannot force the equity value above Nasdaq's strict limits before the final appeal hearing, the backup option under Busch's institutional guidance would likely mean transitioning to trade on the **OTC (Over-the-Counter) Markets**, where the business can continue to scale its oncology platform away from Nasdaq's constant compliance pressure. \[[1](https://www.theglobeandmail.com/investing/markets/stocks/ADTX/pressreleases/2259544/aditxt-appoints-interim-ceo-amid-broad-leadership-transition/), [2](https://www.citybiz.co/article/853549/aditxt-appoints-jeffrey-busch-as-interim-ceo-to-accelerate-commercialization-of-precision-oncology-business/)\]